Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (Q40147477)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 April 2007

Language	Label	Description	Also known as
English	Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis	scientific article published on 9 April 2007

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

author name string

Suzuki E

1

1 reference

Europe PubMed Central

17 September 2017

Umezawa K

2

1 reference

Europe PubMed Central

17 September 2017

Bonavida B

3

1 reference

Europe PubMed Central

17 September 2017

language of work or name

0 references

publication date

9 April 2007

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

26

1 reference

Europe PubMed Central

17 September 2017

42

1 reference

Europe PubMed Central

17 September 2017

6184-6193

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210448

0 references

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

The Akt/PKB pathway: molecular target for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Cellular survival: a play in three Akts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

The multiple roles of PTEN in tumor suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Isolation and characterization of the B-cell marker CD20.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Common genetic variation at PTEN and risk of sporadic breast and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

PI3K-Akt pathway: its functions and alterations in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Epigenetic mechanisms for progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Overview of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Akt signaling and cancer: surviving but not moving on.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Phosphoinositide 3-kinases as targets for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

21 January 2018

Incidence of homogeneously staining regions in non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

7 January 2021

based on heuristic

inferred from DOI database lookup

Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210448

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1210448

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40147477&oldid=1940107984"